Talis Biomedical Corp expected to post a loss of $1.18 a share - Earnings Preview

Talis Biomedical

07/05/2022 03:05

* Talis Biomedical Corp  TLIS.OQ   TLIS.O  is expected
to show a
fall in quarterly revenue when it reports  results on May 10. 
    * The Menlo Park California-based  company is expected to
report 
a 90.7% decrease in revenue to $650 thousand from $7 million a
year ago, according to the mean estimate from 2 analysts, based
on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Talis Biomedical
Corp is
for a loss of $1.18 per share. For the same quarter last year,
the company reported a loss of $4.61 per share.
    * The current average analyst rating on the shares is "sell"
and
the breakdown of recommendations is no "strong buy" or "buy," no
"hold" and 3 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Talis
Biomedical
Corp is $1.25​, above​ its last closing price of $1.09. ​​​

This summary was machine generated May 7 at 02:05 GMT.  All
figures in US dollars  unless otherwise stated